Redx Pharma to present at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans on 20 April
16 Apr 2016
Redx Pharma’s cancer subsidiary, Redx Oncology, has developed novel, differentiated, reversible small molecule inhibitors of Bruton’s tyrosine kinase (BTK) and will be presenting its poster to the scientific community next week at the AACR’s 2016 annual gathering. Redx’s lead compound has a favorable in vitro safety profile and drug-like properties, displaying an improved CYP profile to competitor compounds. In vivo PK demonstrated good oral bioavailability.
This breakthrough is part of Redx’s work to develop best-in-class treatments for leukaemia, other blood cancers, and autoimmune diseases such as rheumatoid arthritis, lupus, and Sjögren’s Syndrome.
Dr Nicolas Guisot will be presenting the program on Wednesday 20 April between 7:30 and 11:00am in Section 19, Poster Board Number 20. If you would like to meet with our scientists or business development team please contact Dr Matilda Bingham, Executive Director of Redx Oncology.
The presentation abstract and author information is available here: